Semaglutide improved maximum walking distance in patients with type 2 diabetes and symptomatic peripheral artery disease.

Semaglutide may relieve peripheral arterial disease experienced by many patients with type 2 diabetes, a new Montreal study ...

A new international study has found that semaglutide, a medication commonly used to treat type 2 diabetes and obesity, ...

The annual meeting of the American College of Cardiology was held from March 29 to 31 in Chicago and attracted more than ...

After 52 weeks of treatment, patients receiving semaglutide experienced a 21% improvement in maximum walking distance compared to just 8% in the placebo group. "The study found a significant ...

Approval would help the company in its head-to-head market battle with main rival Novo Nordisk in the GLP-1 category, whose semaglutide ... their six-minute walking distance test at one year ...

Semaglutide associated with increased walking distance in patients with symptomatic peripheral artery disease and type 2 diabetes.

Researchers from the University of Bern analyzed over 300,000 FDA reports and found semaglutide use was linked to a higher ...